This gives me hope (Japanese study.)

_________

Changes in BMD with romosozumab was also evaluated in postmenopausal Japanese women with osteoporosis.10 Women with a T-score < −2.5 were randomized to romosozumab (70 mg, 140 mg, 210 mg) SQ once monthly for 12 months, or placebo. All romosozumab doses increased BMD compared with placebo (P < .01). Similar to the previous trial, the 210 mg dose produced the largest gain from baseline (16.9%, P < .001), when compared with the 70 and 140 mg dose (8.4%, 13.3%, respectively; P < .001). All doses increased bone formation marker P1NP and decreased bone resorption marker sCTx at week 1, compared with placebo (P < .001). The mean age in this study was 67.7 years with average T-scores of −2.7, −1.9, and −2.3 at the lumbar spine, total hip, and femoral neck, respectively. Adverse events were comparable between the groups.